ライフサイエンスコーパス: Janus kinase

1 plex stabilization related to the associated Janus kinases.

2 we discovered that miR-373 directly targets Janus kinase 1 (JAK1) and IFN-regulating factor 9 (IRF9)

3 f the FERM and SH2-like domains of the human Janus kinase 1 (JAK1) bound to a fragment of the intrace

4 is required for H(2)O(2) responsiveness, and Janus kinase 1 (JAK1) is required for adequate basal sig

5 enes encoding interferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurre

6 mutations, including activating mutations of Janus kinase 1 (JAK1), in 9.1% of patients and provides

7 eron (IFN) signaling antagonist by targeting Janus kinase 1 (JAK1).

8 main-containing protein (RLTPR); moesin; and Janus kinase 1 (JAK1).

9 In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity

10 Expression of the activated form of Janus kinase 1 supported a role for IL-10 in prosurvival

11 validation of one of these candidates, Jak1 (Janus kinase 1), a tyrosine kinase of the nonreceptor ty

12 Finally, we determined that inhibition of Janus kinase 1, inhibition of Glycogen synthase kinase 3

13 10 (IP-10), and the signaling intermediates Janus kinase 1, signal transducer and activator of trans

14 ase 2 study for the treatment of MF with the Janus kinase 1/2 (JAK1/2) inhibitor momelotinib (MMB) de

15 The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the

16 Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evol

17 agues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murin

18 a STAT3/5 inhibitor, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor.

19 Recently, several Janus kinase 1/2 (JAK1/2) inhibitors, such as ruxolitini

20 ) transcription factor and the JAK1/2-STAT3 (Janus Kinase 1/2 - Signal Transducer and Activator of Tr

21 n of STAT1 signaling with the small-molecule Janus kinase 1/2 inhibitor ruxolitinib in vitro and in v

22 Treatment with the Janus kinase 1/2 inhibitor ruxolitinib reduced hyperresp

23 was abrogated by ex vivo treatment with the janus kinase 1/2 inhibitor ruxolitinib.

24 to dexamethasone and INCB018424, a selective Janus kinase 1/2 inhibitor.

25 The Janus kinase 1/3 inhibitor R507 is a very well-tolerated

26 The efficacy of selective Janus kinase 1/3 inhibitor R507 to prevent obliterative

27 treatment with tofacitinib citrate, an oral Janus kinase 1/3 inhibitor, resulted in significant repi

28 facitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional speci

29 dogenously processed K(d)-restricted peptide Janus kinase-1(3)(5)(5)(-)(3)(6)(3) (~15,000 copies/cell

30 ssor pathway (54%), Ras signaling (50%), and Janus kinases (11%).

31 notypic consequence of the V617F mutation in Janus kinase 2 (encoded by JAK2), but the extent to whic

32 uired gain-of-function V617F mutation in the Janus Kinase 2 (JAK2(V617F)) is the main mutation involv

33 etic deletion in the hematopoietic system of Janus kinase 2 (JAK2) abrogates initiation of myeloproli

34 prevented the decrease of phosphorylation of Janus kinase 2 (JAK2) and phosphorylation of signal tran

35 nhibits interferon-gamma (IFN-gamma)-induced Janus kinase 2 (JAK2) and signal transducer and activati

36 sulting in a loss of downstream signaling by Janus kinase 2 (JAK2) and signal transducer and activato

37 ndocytic AMR controls TPO expression through Janus kinase 2 (JAK2) and the acute phase response signa

38 he prolactin receptor (PRLR), its associated Janus kinase 2 (Jak2) and the signal transducer and acti

39 Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for th

40 dermal growth factor receptor (EGFR) utilize Janus kinase 2 (JAK2) as a common signaling node to tran

41 Here, we investigated the role of Janus kinase 2 (JAK2) as a newly described intracellular

42 The nonreceptor kinase Janus kinase 2 (JAK2) has garnered attention as a promis

43 s) is the acquisition of a V617F mutation in Janus kinase 2 (JAK2) in hematopoietic stem cells (HSCs)

44 ine kinase (IRTK) and leptin receptor (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.

45 ETE also induced tyrosine phosphorylation of Janus kinase 2 (Jak2) in VSMCs, and its inhibition subst

46 tive to TG101348, a selective small-molecule Janus kinase 2 (JAK2) inhibitor.

47 ncreatic tumors were given gemcitabine and a Janus kinase 2 (JAK2) inhibitor; tumor growth was monito

48 Developing Janus kinase 2 (Jak2) inhibitors has become a significan

49 Janus kinase 2 (JAK2) is a central kinase in hematopoiet

50 quired for adequate basal signaling, whereas Janus kinase 2 (JAK2) is dispensable upstream of STAT3.

51 "TET2-first patients"), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ("JAK2

52 Janus kinase 2 (JAK2) mutations define polycythemia vera

53 eedforward loop in which p27pT157pT198 binds Janus kinase 2 (JAK2) promoting STAT3 (signal transducer

54 Expression of Janus kinase 2 (JAK2) R867Q and S755R/R938Q induced spon

55 We recently developed a Janus kinase 2 (Jak2) small molecule inhibitor called G6

56 on of the phosphoinositol 3-kinase (PI3K) or Janus kinase 2 (Jak2) tyrosine kinase inhibitors abolish

57 The Janus kinase 2 (JAK2) V617F mutation is the primary path

58 combined targeting of the BCR-ABL kinase and Janus kinase 2 (JAK2) with dasatinib and ruxolitinib, re

59 anism that is dependent upon beta1 integrin, Janus kinase 2 (JAK2), and STAT3 but not EGFR.

60 Phosphorylated STAT3, phosphorylated Janus kinase 2 (JAK2), and suppressor of cytokine signal

61 and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myelopro

62 receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurrent with deletion of the w

63 Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosin

64 tracytoplasmic tyrosine kinases, essentially janus kinase 2 (JAK2), which regulates MPL stability and

65 culin (CALR) mutations have been reported in Janus kinase 2 (JAK2)- and myeloproliferative leukemia (

66 red the human PRL-prolactin receptor (hPRLR)-Janus kinase 2 (JAK2)-signal transducer and activator of

67 we demonstrated that inhibition of the IL-6-Janus kinase 2 (JAK2)-STAT3-calprotectin axis with FDA-a

68 uences of Stat1 deficiency on the effects of Janus kinase 2 (JAK2)-V617F in vivo by crossing mice exp

69 short-interfering RNA-mediated knockdown of Janus kinase 2 (JAK2).

70 ting mutations of signaling proteins such as Janus kinase 2 (JAK2).

71 sential thrombocythemia (ET) with nonmutated Janus kinase 2 (JAK2).

72 Blockade of HGF/Met, Janus kinase 2 (JAK2)/STAT3 and TGF-beta1 signaling by s

73 ulated by retinoic acid 6" (STRA6), enhanced Janus kinase 2 (JAK2)/STAT5 cascade, up-regulated adenyl

74 The inclusion of a transgenic allele of Janus kinase 2 (JAK2)V617F resulted in acceleration of t

75 patients have a gain of function mutation in Janus kinase 2 (JAK2V617F), but little is known how JAK2

76 Mice with hepatocyte-specific deletion of Janus kinase 2 (L-JAK2 KO mice) develop spontaneous stea

77 r (MPL) to induce constitutive activation of Janus kinase 2 and signal transducer and activator of tr

78 ompounds are designed to bind selectively to Janus kinase 2 and the STAT3 Src homology-2 domain, whic

79 Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloproliferat

80 rimary myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to 10% h

81 Inhibition of Janus kinase 2 or SRC kinase signaling downstream of mut

82 In addition, the rate of Janus kinase 2 phosphorylation, initiated through the th

83 x O1, extracellular signal-regulated kinase, Janus kinase 2, or signal transducers and activators of

84 tes the formation of a complex with IRS2 and Janus kinase 2, preventing IRS2 ubiquitination.

85 he phosphorylation of Lyn, the Epo receptor, Janus kinase 2, Signal Transducer and Action of Transcri

86 d PD-L2, and their further induction through Janus kinase 2-signal transducers and activators of tran

87 ic kidney 293T cells that express endogenous Janus kinase 2.

88 s could be reversed by administration of the Janus kinase 2/3 inhibitor tofacitinib, which blocks IL-

89 d this required intact signaling through the Janus Kinase 2/phosphatidylinositol-4,5-bisphosphate 3-k

90 oid progenitors EPOR engagement of canonical Janus kinase 2/signal transducer and activator of transc

91 The Janus kinase 2/signal transducers and activators of tran

92 Janus kinase-2 (JAK2) conveys receptor-binding signals b

93 The critical role of Janus kinase-2 (JAK2) in regulation of myelopoiesis was

94 Mutations in Janus kinase-2 (JAK2) occur in approximately 50% of pati

95 zed the response of bone to GH by increasing Janus kinase-2 and IGF-1R protein levels.

96 ing is well known to regulate lymphopoiesis, Janus kinase 3 (JAK3) also plays a critical role in prom

97 Phosphorylation of Janus kinase 3 (JAK3) and signal transducers and activat

98 Mutations in Janus kinase 3 (JAK3) are a cause of severe combined imm

99 SGs was prevented through the activation of Janus kinase 3 (JAK3) by the vitamin K3 analog menadione

100 NK cells on SIV infection, use was made of a Janus kinase 3 (JAK3) inhibitor that has previously been

101 Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase e

102 Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase e

103 Although constitutive activation of Janus kinase 3 (Jak3) leads to different cancers, the me

104 ling pathway mutations, including activating Janus kinase 3 (JAK3) mutations, were detected.

105 microarray-based analyses and showed reduced Janus kinase 3 (JAK3) phosphorylation upon activation.

106 mitogen-activated protein kinase (MAPK), and Janus kinase 3 (JAK3) signaling are necessary for F. tul

107 The Janus kinase 3 (JAK3) tyrosine kinase is mutated in 10%

108 phospholipase D2 (PLD2) is under control of Janus kinase 3 (JAK3), which mediates chemotaxis.

109 lso report that PLD2 is under the control of Janus kinase 3 (JAK3), with the kinase phosphorylating P

110 receptor common gamma chain cytokines and a Janus kinase 3 (JAK3)-dependent pathway in malignant T c

111 ), DNA-dependent protein kinase (prkdc), and janus kinase 3 (jak3).

112 ations are usually absent in the SCID-X1 and Janus kinase 3 forms of SCID and greatly reduced in aden

113 vide adequate immunosuppression, whereas the Janus kinase 3 inhibitor tofacitinib's success in the tr

114 We reported previously that Janus kinase 3, a non-receptor tyrosine kinase, plays a

115 -beta-induced Treg development, and inhibits Janus kinase 3-induced STAT5 phosphorylation, a transcri

116 els trigger signaling through Rho kinase and Janus kinase-3, and cause actin remodeling.

117 et al. (2015) uncover multifaceted roles for janus kinase and microtubule-interacting protein 1 (JAKM

118 We originally identified Janus kinase and microtubule-interacting protein 1 (JAKM

119 gh several signaling pathways, including the Janus kinase and signal transducer and activator (JAK-ST

120 gnal from the hub cells, which activates the Janus Kinase and Signal Transducer and Activator of Tran

121 Chronic activation of Janus kinase and signal transducer and activator of tran

122 by pathological activation of the JAK/STAT (Janus kinase and signal transducer and activator of tran

123 p38 mitogen-activated protein kinase (p38), Janus kinases and IL-6 have also shown some promising ef

124 eously secrete IL-17F and that inhibitors of Janus kinases and Signal transducer and activator of tra

125 Small-molecule inhibitors of the Janus kinase family (JAKis) are clinically efficacious i

126 s downstream of gp130 involved the classical Janus kinase family-signal transducer and activator of t

127 Activation of the Janus kinase family/signal transducer and activator of t

128 Kinases of the Jak ('Janus kinase') family and transcription factors (TFs) of

129 ort a model of nonhierarchical activation of Janus kinases in which one catalytically competent Jak i

130 ate antiviral receptor) and TYK2 (encoding a Janus kinase), in each case establishing a further serie

131 Other promising drugs focus on blockade of Janus kinase, inhibition of various chemokines, and biol

132 The Janus kinase inhibitor AG490 and the Src kinase inhibito

133 ggered Bcl-6 expression in MM cells, whereas Janus kinase inhibitor and STAT3 siRNA down-regulated Bc

134 Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.

135 Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid a

136 egimen of tofacitinib (CP-690, 550), an oral Janus kinase inhibitor or cyclosporine (CsA).

137 Although the Janus kinase inhibitor ruxolitinib provides symptomatic

138 cription 3 dependent and was impaired by the Janus kinase inhibitor ruxolitinib.

139 Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated as a t

140 Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated for th

141 Tofacitinib is an oral Janus kinase inhibitor that is under investigation for t

142 Tofacitinib, an oral Janus kinase inhibitor that targets Jak1/Jak3 dependent

143 Tofacitinib is a novel, oral, Janus kinase inhibitor that treats RA.

144 Janus kinase inhibitor therapy could represent an effect

145 Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent ef

146 Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treat

147 A new Janus kinase inhibitor, tofacitinib (CP-690550), has sho

148 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential effi

149 The introduction of Janus kinase inhibitors for myelofibrosis have ushered i

150 of the pathogenesis of vitiligo suggest that Janus kinase inhibitors may be a therapeutic option.

151 e results suggest that tofacitinib and other Janus kinase inhibitors may be effective in the treatmen

152 an agonist of the aryl hydrocarbon receptor, Janus kinase inhibitors, and commensal organisms also in

153 afety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with t

154 Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have

155 Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant a

156 Janus kinase (JAK) 1/JAK2 inhibitors are in development

157 ple signal-transduction pathways, among them janus kinase (JAK) 2-signal transducer and activator of

158 Activating Janus kinase (JAK) and signal transducer and activator o

159 was recently shown to regulate Stat92E, the Janus kinase (JAK) and Signal transducer and activator o

160 Genetic alterations affecting members of the Janus kinase (JAK) family have been discovered in a wide

161 y administered pharmacological inhibitors of Janus kinase (JAK) family protein tyrosine kinases, down

162 The Janus kinase (JAK) inhibitor ruxolitinib is the only app

163 cytokine-signaling inhibitor tofacitinib, a Janus kinase (JAK) inhibitor targeting JAK3 and JAK1.

164 Intriguingly, treatment of T cells with the Janus kinase (JAK) inhibitor tofacitinib disproportionat

165 from patients with myelofibrosis (MF) to the Janus kinase (JAK) inhibitor, AZD1480.

166 oplasms (MPN) led to clinical development of Janus kinase (JAK) inhibitors for treatment of MPN.

167 ies on the mechanism of action of successful Janus kinase (Jak) inhibitors have revealed that, apart

168 More recently, clinical trials with Janus kinase (JAK) inhibitors have shown that cytokine r

169 iption 1 (STAT1), so we tested the effect of Janus kinase (JAK) inhibitors on STAT1 phosphorylation i

170 hod for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond t

171 neoplasm-associated myelofibrosis, including Janus kinase (JAK) inhibitors, do not induce complete or

172 a-derived conditions enhanced sensitivity to Janus kinase (JAK) inhibitors.

173 The Janus kinase (JAK) pathway is an essential, highly re-ut

174 We show that Janus kinase (JAK) protein tyrosine kinases control chem

175 ransport, holo-RBP can activate STRA6-driven Janus kinase (JAK) signaling and downstream induction of

176 The mechanistic link between Janus kinase (JAK) signaling and structural damage to ar

177 ells mediate alopecia areata in part through Janus kinase (JAK) signaling and that alopecia areata mi

178 rylation in AML leukemic blasts, the role of Janus kinase (JAK) signaling in primary AML compared wit

179 The Janus kinase (JAK) system is involved in numerous cell s

180 t clones with constitutive activation of the Janus kinase (JAK)- signal transducer and activator of t

181 The Janus kinase (JAK)-inhibitor ruxolitinib decreases const

182 d PD-L2, and promote their induction through Janus kinase (JAK)-signal transducer and activator of tr

183 Dysregulation of Janus kinase (JAK)-signal transducer and activator of tr

184 The discovery of the Janus kinase (JAK)-signal transducer and activator of tr

185 hain (gamma(c)) cytokines signal through the Janus kinase (JAK)-signal transducer and activator of tr

186 tions that are either functionally linked to Janus kinase (JAK)-signal transducer and activator of tr

187 of R. conorii infection on the status of the Janus kinase (JAK)-signal transducer and activator of tr

188 The Janus kinase (JAK)-signal transducer and activator of tr

189 The Janus kinase (JAK)-signal transducer of activators of tr

190 clear factor-kappaB signaling pathway or the Janus kinase (JAK)-signal transducers and activators of

191 We demonstrate that the I. scapularis Janus kinase (JAK)-signaling transducer activator of tra

192 n of adult retinal ganglion cells (RGCs) via Janus kinase (JAK)-STAT3 signalling.

193 Chronic activation of the Janus kinase (JAK)/signal transducer and activator of tr

194 Evidence suggests a role for the Janus kinase (JAK)/signal transducer and activator of tr

195 Because in various cells activation of the Janus kinase (JAK)/signal transducer and activator of tr

196 ent study was to investigate the role of the Janus kinase (JAK)/signal transducer and activator of tr

197 diabetes complications, such as elements of Janus kinase (JAK)/signal transducer and activator of tr

198 egulation of Jun N-terminal Kinase (JNK) and Janus Kinase (JAK)/Signal Transducer and Activator of Tr

199 The Janus kinase (JAK)/signal transducer and activator of tr

200 ncubation with ToxB activated a proapoptotic Janus kinase (JAK)/signal transducer and activator of tr

201 Finally, we demonstrate that Janus kinase (JAK)/signal transducer and activator of tr

202 Frequent mutations in cytokine receptor and Janus kinase (JAK)/signal transducer and activator of tr

203 Activation of the Janus kinase (JAK)/signal transducer and activator of tr

204 leukaemia-initiation potential and activated Janus kinase (JAK)/signal transducers and activators of

205 e) inducing a constitutive activation of the Janus kinase (JAK)/STAT pathway.

206 n the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK)1 and JAK2 inhibitor, was superior to

207 This is the first report on the novel Janus kinase (JAK)1/3 inhibitors R507 and R545 for preve

208 Ruxolitinib is a potent Janus kinase (JAK)1/JAK2 inhibitor that has demonstrated

209 mutation leads to constitutive activation of Janus kinase (JAK)2 and contributes to dysregulated JAK

210 The discovery of the Janus kinase (JAK)2 mutation triggered the development o

211 The Janus kinase (JAK)2/signal transducer and activator of t

212 or hetero-dimeric cell surface receptors via Janus Kinase (JAK/TYK), or Receptor Tyrosine Kinase (RTK

213 results in activation of receptor-associated Janus kinases (Jak) and phosphorylation of STAT proteins

214 Janus kinases (Jak) play essential roles in cytokine and

215 nds (IFNalpha/beta) or catalytic activity of Janus kinases (JAK).

216 uch cases harboring somatic mutations in the Janus kinases JAK1 and JAK2.

217 Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved

218 ansduces a signaling cascade mediated by the Janus kinase JAK2 and the transcription factors STAT3 an

219 e prototypical upstream kinase of STAT5, the Janus kinase JAK2, in CML is still under debate.

220 For this, they differentially use the Janus kinase (Jak2) and phosphatidylinositol 3-kinase (P

221 /radixin/moesin domain-containing protein of Janus kinase (JAK2) as demonstrated by the reciprocal im

222 ese cytokines to their downstream effectors, Janus kinases (JAKs) and signal transducers and activato

223 We uncovered signaling mediated by Janus kinases (Jaks) and the transcription factor Stat3

224 The Janus kinases (JAKs) and their downstream effectors, sig

225 The Janus kinases (JAKs) are a family of intracellular tyros

226 The Janus kinases (JAKs) are involved in multiple signaling

227 Janus kinases (JAKs) are nonreceptor tyrosine kinases wi

228 Janus kinases (JAKs) are receptor-associated multidomain

229 Janus kinases (JAKs) are regulators of signaling through

230 Activated Janus kinases (JAKs) are required for T-effector cell re

231 s a key mechanism for the transactivation of Janus kinases (Jaks) bound at the intracellular receptor

232 Janus kinases (JAKs) classically signal by activating ST

233 The data revealed that Janus kinases (JAKs) couple IL-2 receptors to the coordi

234 TATs), essential functions of their upstream Janus kinases (JAKs) during postnatal development are le

235 The action of Janus kinases (JAKs) is required for multiple cytokine s

236 The Janus kinases (JAKs) transduce signals initiated followi

237 ellular signal-regulated kinase (Erk)1/2 and janus kinases (Jaks), aberrant signal transducer and act

238 signaling molecules, including ERK, Akt, and Janus kinases (Jaks), especially those that mediate infl

239 orylated potentially on the basis of reduced Janus kinase-mediated inhibition of protein phosphatase

240 Paradoxically, IFN1-induced Janus kinase-mediated phosphorylation of Y466 is expecte

241 or molecules to make room for the associated Janus kinase molecules, while the self-rotation allows t

242 hocytes, PDE4, the histamine 4 receptor, and Janus kinase) or specifically itching (eg, NK1R inhibito

243 adhesion kinase, protein tyrosine kinase-2, Janus kinase, other focal adhesion-associated proteins,

244 ic FXR hyperacetylation and induction of the Janus kinase/p53 pathway.

245 Signaling from JAK (Janus kinase) protein kinases to STAT (signal transducer

246 b and ruxolitinib, which inhibit BCR-ABL and Janus kinases, respectively), significantly extends surv

247 N including utilization of the intracellular Janus kinase signal transducer and activator of transcri

248 Socs36E encodes an inhibitor of the Janus kinase signal transducer and activator of transcri

249 n ALL, including tumor suppressors, Ras, and Janus kinase-signal transducer and activator of transcri

250 erization domain-like receptor signaling and Janus kinase-signal transducer and activator of transcri

251 a higher frequency of mutations outside the Janus kinase-signal transducer and activator of transcri

252 Mechanistically, loss of SH2B3 increases Janus kinase-signal transducer and activator of transcri

253 2V617F exerts its effects on cell growth via janus kinase-signal transducer and activator of transcri

254 nd the effects HEV has on IFN-alpha-mediated Janus kinase-signal transducer and activator of transcri

255 a stem cell niche by locally activating the Janus Kinase-Signal Transducer and Activator of Transcri

256 The JAK-STAT (Janus kinase-signal transducer and activator of transcri

257 Dysregulated Janus kinase-signal transducer and activator of transcri

258 cells whose development is dependent on the Janus kinase-signal transducer and activator of transcri

259 cation after blocking the interferon-induced Janus kinase-signal transducer and activator of transcri

260 as the phosphoinositide 3-kinase (PI3K) and Janus kinase-signal transducer and activator of transcri

261 n Drosophila by the evolutionarily conserved Janus kinase-signal transducers and activators of transc

262 Combined, these data show that an IL-10/Janus kinase/signal transducer and activator of transcri

263 induce Bim in normal and ALPS T cells via a Janus kinase/signal transducer and activator of transcri

264 The Janus kinase/signal transducer and activator of transcri

265 ays, such as TCRs, nuclear factor kappaB, or Janus kinase/signal transducer and activator of transcri

266 ingless-related integration site), JAK-STAT (Janus kinase/signal transducer and activator of transcri

267 cell-like diffuse cell lymphoma and enhanced Janus kinase/signal transducer and activator of transcri

268 e signature in CLL, containing components of Janus kinase/signal transducer and activator of transcri

269 grate toward the source by activation of the Janus kinase/signal transducer and activator of transcri

270 The Janus kinase/signal transducer and activator of transcri

271 alone produced IL-2/IL-9, and the downstream Janus kinase/signal transducer and activator of transcri

272 It is known that Janus kinase/signal transducer and activator of transcri

273 origenic overgrowth by exploiting endogenous Janus kinase/signal transducer and activator of transcri

274 Conserved from humans to Drosophila, the Janus kinase/signal transducer and activators of transcr

275 Here, we emphasize Janus kinase/signal transducers and activators of transc

276 Accumulating evidence points to a role for Janus kinase/signal transducers and activators of transc

277 erleukin-6 (IL-6) secretion, which activates Janus kinase/signal transducers and activators of transc

278 Secreted IFNs activate the Janus kinase/signal transducers and activators of transc

279 e that IL-4 up-regulates pIgR production via Janus kinase/signal transducers and activators of transc

280 The Janus kinase/Signal transducers and activators of transc

281 ds of the Unpaired (Upd) family activate the Janus kinase/signal transducers and activators of transc

282 ignalling 3 (SOCS3), a negative regulator of Janus kinase/signal transducers and activators of transc

283 Mechanistically, IRS-1 deficiency promotes Janus kinase/signal transducers and activators of transc

284 Inhibition of Janus kinase signaling during controlled mechanical vent

285 ndent of IFNalpha, IFNbeta, IFNL1, IFNL2, or Janus kinase signaling via signal transducer and activat

286 d with CMV can be prevented by inhibition of Janus kinase signaling.

287 late kinases known to activate Stat3 such as Janus kinases, Src kinase family members or receptor tyr

288 The MEK inhibitor trametinib, the Janus kinase-STAT inhibitor tofacitinib, and the STAT5 i

289 am transcriptional program and activates the Janus kinase-STAT signaling cascade and thus, by interfe

290 with the IL28B-T/T variant preactivates the Janus kinase-Stat signaling, leading to impaired HCV cle

291 Prior janus kinase/STAT inhibition with AG490 in vivo abrogate

292 by regulating retinal Epo expression through Janus kinase/STAT signaling.

293 iasis: (1) rapid attenuation of keratinocyte Janus kinase/STAT signaling; (2) removal of keratinocyte

294 MM cells is modulated, at least in part, via Janus kinase/STAT3 and canonical nuclear factor-kappaB p

295 y indicated potential negative regulation of Janus kinase/Stat3 pathway in pM-treated cells.

296 rget three major cellular processes: (i) the Janus kinase/STAT5 pathway (ii) progenitor B-cell differ

297 y, binding of agonist to receptors activates Janus kinases that phosphorylate cytoplasmic STAT3 at ty

298 The Janus kinase tyrosine kinase (Tyk) 2 associates with IL-

299 and stabilize the pseudokinase domain of the Janus kinase tyrosine kinase 2 (Tyk2), resulting in bloc

300 lated protein kinases, protein kinase B, and Janus kinase, which are activated by chemotherapeutics i